Chemical Linker Technology as a composition of Antibody Drug Conjugates

LONGWOOD, Fla. - Feb. 5, 2015 - PRLog -- USA Florida, February 05, 2015

The key components of GAP antibody drug conjugate technology are the stable linkers and the synthetic cytotoxic agents. The antibody drug conjugates are attached by the chemical linkers with labile bonds.

By combining the unique targeting of monoclonal antibodies with the cancer killing ability of cytotoxic drugs, it permits sensitive bias between healthy and tissue having diseases.  The progresses in antibodies coupling to cytotoxic drugs permits better control of pharmacokinetics of drug and significantly improve delivery to target tissue. Effective anti cancer drugs which are new can now be used to target cancers though minimizing exposure of healthy tissue.

The antibodies having therapeutic potential are enhanced by conjugating them to drugs of small molecule. This combination coalesce the benefits of highly potent drugs with selective binders of tumor antigens specifically. ADC offers the promise of delivering more powerful tumor-killing activity while resulting in diminished side effects for cancer patients.

Antibody drug conjugates currently are getting a lot of attention from the public and as people continue to wonder how it works. There are mainly two types of chemical linkers, they are either cleavable or non cleavable. The cleavable type includes Disulfides, hydrazones &peptides and the non cleavable type includes Thio ethers.

When it comes to the Cleavable type , the cancer cells have certain types of enzymes that induces catalysis to the linker , which leads to the release of the biological toxin that kills the cancer cell but sometimes it can escape from targeted cancer cells , and kill those that are next to it (also cancerous cells) that’s called Bystander killing.

While the Non-cleavable type has a different story, it leads to keeping the whole conjugate drug within the cell, and later on the linker degrades into amino acids along with the antibody and the cytotoxin, which becomes what we call the active drug that works on the cancerous cell and have a lesser chance of escaping into the cells next to the one targeted.

Brentuximab which has a cleavable linker that is enzyme sensitive and the cytotoxin it carries is very toxic called MMAE , and because of this harmful toxicity it can’t be used alone without combination with another agent , yet if it is combined with anti CD30 , it can show stability in the extracellular fluid .

Research is going on currently to develop a new kind of chemical linkers. That allows the scientists to work with more flexibility without any form of worry over the kinetics of cleavage. As well as, how it changes and they are accomplishing that by the addition of an extra molecule among the cytotoxin and the site of cleavage.

GAP has more than a decade of experience in Antibody Drug Conjugate (ADC) technologies, which make powerful monoclonal antibodies to treat the targeted diseased area more effectively. GAP oncology Team has an expert panel which helps the patients in planning their treatment strategy throughout their fight against cancer.

contact at:160 Vista Oak Dr.
Longwood, FL 32779
Telephone: 321-445-1969

Email id : info@gapsos.com

website :www.gapsos.com